CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS | stella

Learn Data For Researchers Find trials matched to me

Learn Data For Researchers Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS | stella

Back to Amyotrophic Lateral Sclerosis trials

Active, not recruiting

Plain-English translation of NCT05306457 on ClinicalTrials.gov ↗ · Source last updated August 2025 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(1 site)

United States

Cedars-Sinai Medical Center, Los Angeles, California

Key details

Phase

Safety & dosing

Sponsor

Cedars-Sinai Medical Center

Collaborators

California Institute for Regenerative Medicine (CIRM)

Enrollment target

~16 participants

Started

May 2022

Primary completion

October 2026

View full record on ClinicalTrials.gov

Age range

18 Years and older

Last updated on clinicaltrials.gov in August 2025.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.